EICHORCondition: Systemic Sclerosis · Sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to determine whether itacitinib is safe and effective in the treatment of systemic sclerosis in adults.
This description comes directly from the study's public registry record.
Benjamin Chaigne, MD · +33 1 58 41 41 17 · benjamin.chaigne@aphp.fr
Adèle BELLINO · +33 1 58 41 11 95 · adele.bellino@aphp.fr
Always discuss trial participation with your own doctor first.
| CH Amiens | Amiens, France | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| CHU Annecy | Annecy, France | Recruiting |
| CHU Besançon | Besançon, France | Recruiting |
| Avicenne Hospital | Bobigny, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| CHU Bordeaux | Bordeaux, France | Recruiting |
| Ambroise Paré hospital | Boulogne-Billancourt, France | Recruiting |
| Hôpital de la Cavale Blanche | Brest, France | Recruiting |
| CHU Caen | Caen, France | Recruiting |
| CHU Gabriel Montpied | Clermont-Ferrand, France | Recruiting |
| Henry Mondor hospital | Créteil, France | Recruiting |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04789850